Historical Valuation
Bristol-Myers Squibb Co (BMY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.40 is considered Undervalued compared with the five-year average of 11.33. The fair price of Bristol-Myers Squibb Co (BMY) is between 64.07 to 83.89 according to relative valuation methord. Compared to the current price of 55.86 USD , Bristol-Myers Squibb Co is Undervalued By 12.82%.
Relative Value
Fair Zone
64.07-83.89
Current Price：55.86
12.82%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Bristol-Myers Squibb Co (BMY) has a current Price-to-Book (P/B) ratio of 5.87. Compared to its 3-year average P/B ratio of 5.13 , the current P/B ratio is approximately 14.26% higher. Relative to its 5-year average P/B ratio of 4.78, the current P/B ratio is about 22.83% higher. Bristol-Myers Squibb Co (BMY) has a Forward Free Cash Flow (FCF) yield of approximately 14.06%. Compared to its 3-year average FCF yield of 11.88%, the current FCF yield is approximately 18.39% lower. Relative to its 5-year average FCF yield of 10.82% , the current FCF yield is about 29.96% lower.
P/B
Median3y
5.13
Median5y
4.78
FCF Yield
Median3y
11.88
Median5y
10.82
Competitors Valuation Multiple
AI Analysis for BMY
The average P/S ratio for BMY competitors is 4.31, providing a benchmark for relative valuation. Bristol-Myers Squibb Co Corp (BMY.N) exhibits a P/S ratio of 2.40, which is -44.28% above the industry average. Given its robust revenue growth of 2.77%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BMY
1Y
3Y
5Y
Market capitalization of BMY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BMY in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BMY currently overvalued or undervalued?
Bristol-Myers Squibb Co (BMY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.40 is considered Undervalued compared with the five-year average of 11.33. The fair price of Bristol-Myers Squibb Co (BMY) is between 64.07 to 83.89 according to relative valuation methord. Compared to the current price of 55.86 USD , Bristol-Myers Squibb Co is Undervalued By 12.82% .
What is Bristol-Myers Squibb Co (BMY) fair value?
BMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bristol-Myers Squibb Co (BMY) is between 64.07 to 83.89 according to relative valuation methord.
How does BMY's valuation metrics compare to the industry average?
The average P/S ratio for BMY's competitors is 4.31, providing a benchmark for relative valuation. Bristol-Myers Squibb Co Corp (BMY) exhibits a P/S ratio of 2.40, which is -44.28% above the industry average. Given its robust revenue growth of 2.77%, this premium appears unsustainable.
What is the current P/B ratio for Bristol-Myers Squibb Co (BMY) as of Jan 13 2026?
As of Jan 13 2026, Bristol-Myers Squibb Co (BMY) has a P/B ratio of 5.87. This indicates that the market values BMY at 5.87 times its book value.
What is the current FCF Yield for Bristol-Myers Squibb Co (BMY) as of Jan 13 2026?
As of Jan 13 2026, Bristol-Myers Squibb Co (BMY) has a FCF Yield of 14.06%. This means that for every dollar of Bristol-Myers Squibb Co’s market capitalization, the company generates 14.06 cents in free cash flow.
What is the current Forward P/E ratio for Bristol-Myers Squibb Co (BMY) as of Jan 13 2026?
As of Jan 13 2026, Bristol-Myers Squibb Co (BMY) has a Forward P/E ratio of 8.65. This means the market is willing to pay $8.65 for every dollar of Bristol-Myers Squibb Co’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Bristol-Myers Squibb Co (BMY) as of Jan 13 2026?
As of Jan 13 2026, Bristol-Myers Squibb Co (BMY) has a Forward P/S ratio of 2.40. This means the market is valuing BMY at $2.40 for every dollar of expected revenue over the next 12 months.